Compare TG Therapeutics Inc (TGTX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Upwork Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Upwork Inc trades at $8.24 (market cap $1.03B). The key difference: TG Therapeutics Inc is far larger — about 8.1× Upwork Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | UPWK | |
|---|---|---|
Market Cap | $8.36B | $1.03B |
Sector | Health | Industrials |
52-Week High | $59.06 | $22.11 |
52-Week Low | $26.94 | $7.84 |
Enterprise Value | $8.57B | $791.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Upwork (UPWK) trades at $8.32, down 5.35% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with strong gross margins of 77.21% but declining net income margins from 28.02% in 2024 to 14.65% in 2025. Recent Q2 2026 earnings beat expectations but weak guidance triggered a selloff. Analyst consensus remains positive with a $9.00 price target despite ongoing securities fraud investigations.
The stock presents a value opportunity with low P/E of 10.67 and P/S of 1.44, but faces significant headwinds from AI disruption to freelance demand and multiple legal investigations. Near-term performance depends on management's ability to navigate AI transition while maintaining client growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
